A Phase 2 interventional study of Tofacitinib ointment 20mg/g and Placebo ointment (Vehicle) in Dermatitis, Atopic, sponsored by Pfizer. Completed at 5 sites in Canada. Open to participants aged 18 Years to 60 Years. Per ClinicalTrials.gov, last updated 2015-10-15.
Sponsored by Pfizer · Phase 2, Interventional, and Treatment
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 58 studies in Dermatitis, Atopic by Pfizer — 11 open to participants now, 13 under way, 4 of them phase 3. Dermatitis, Atopic · Pfizer.
Among the 58 studies in Dermatitis, Atopic by Pfizer, this one is the 32nd largest by enrollment of the 47 interventional ones that give a count, is the only one that started in 2013, is one of 13 in phase 2, and was the 5th registered.
1,594 studies on the registry are indexed under Dermatitis, Atopic; 287 are open to participants now.
Browse Dermatitis, Atopic studies →11 of the 58 studies in Dermatitis, Atopic by Pfizer are open now, in 12 countries. Recruiting first, the newest first:
Pfizer · Sites in United States, Canada, Japan and 1 more country
Ages 12+
Pfizer · Sites in United States, Canada, Japan
Ages 12+
Pfizer · Sites in United States
Ages 12+
Pfizer · Sites in United States, China, Hungary and 4 more countries
Ages 2–11
Pfizer · Sites in United States, Bulgaria, Canada and 6 more countries
Ages 18–64
By country, each count listing its studies:
Of the 194 Dermatitis, Atopic studies recruiting now, 83 (43%) set no upper age limit and 95 (49%) stop at 75 or younger; 94 take children under 18; 51 take healthy volunteers.
This study: 18 Years to 60 Years · all sexes · no healthy volunteers.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
58 studies; the count open now beside each. This study's row is marked.
A study in two phases is counted once above. Listed by phase, each with its combined phases: Phase 1 14 · Phase 2 15 · Phase 3 18 · Phase 4 2
First in 2009; this study’s year is marked. 1 started in 2013.
By drug class, each counting the studies that test any of its medicines:
This study's enrollment of 69 is below the median of 82 across 1,248 interventional studies indexed under Dermatitis, Atopic.
Median enrollment 121 across the 47 interventional studies, 150 across the 9 observational. Of the 43 that completed or were terminated, 34 (79%) have results posted.
This tab as a report to print or save as PDF → With an account.
Pfizer is the lead sponsor of 3,337 studies on the registry; 150 are open to participants now.
Of its 601 completed or terminated interventional studies of FDA-regulated products, 392 (65%) have results posted.
4 of the studies in Dermatitis, Atopic by Pfizer that are under way reach primary completion within a year, 0 of them phase 3. Phase 3 first, then by date:
| Study | Primary completion |
|---|---|
| NCT06899204PfizerReal World Efficiency of Abrocitinib Treatment at Patients With Moderate to Severe Atopic Dermatitis Who Had Inadequate Response to Previous Biologic Therapies. | 2027-02-15 |
| NCT06564389PfizerFIH Study to Evaluate the Tolerability of PF-07832837 in Healthy Adults and Patients | 2027-06-02 |
| NCT07887867PfizerA Study to Learn About the Study Medicine Abrocitinib in People With Severe Atopic Dermatitis Who Have Switched From Other Therapies | 2027-10-01 |
| NCT05391061PfizerA Study to Learn About the Study Medicine (Called Cibinqo) in People With Atopic Dermatitis | 2027-11-22 |
Add all 4 to your calendar (.ics) → With an account.
Among the 58 studies in Dermatitis, Atopic by Pfizer, from their registry updates:
This tab as a report to print or save as PDF → With an account.
The study is being conducted to evaluate the efficacy, safety and tolerability of 2% tofacitinib ointment (20 mg/g) BID (twice daily) in subjects with mild to moderate atopic dermatitis compared to placebo (vehicle) BID for 4 weeks.
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Exclusion Criteria:
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).
Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.
Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.
Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.
Childbearing potential
Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).
Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Contraception
Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.
Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Drug: Tofacitinib ointment 20mg/g
Drug: Placebo ointment (Vehicle)
Drug page: Tofacitinib
Tofacitinib ointment 20mg/g twice daily (BID) for 4 weeks
Placebo ointment (vehicle) twice daily (BID) for 4 weeks
Percent Change From Baseline in Eczema Area and Severity Index (EASI) Total Score at Week 4
The EASI quantifies the severity of a participant's atopic dermatitis based on both lesion severity and the percent of BSA affected. The EASI is a composite scoring by the atopic dermatitis clinical evaluator of the degree of erythema, induration/papulation, excoriation, and lichenification (each scored separately) for each of 4 body regions, with adjustment for the percent of BSA involved for each body region and for the proportion of the body region to the whole body. The EASI score can vary in increments of 0.1 and range from 0.0 to 72.0, with higher scores representing greater severity of atopic dermatitis. What is reported is the percent change from baseline in EASI scores.
Time frame: Baseline (pre-dose on Day 1) and Week 4
Proportion of Participants Achieving Physician's Global Assessment (PGA) Response of Clear or Almost Clear at Week 4
The PGA score assesses the overall severity of atopic dermatitis. Scores range from 0 to 4 and correspond to a category (clear, almost clear, mild, moderate, and severe, respectively) based on morphological descriptors.
Time frame: Week 4
Proportion of Participants With Response of Clear or Almost Clear and Greater Than or Equal to (>=) 2 Grade/Point Improvement From Baseline at Week 4
The PGA score assesses the overall severity of atopic dermatitis. Scores range from 0 to 4 and correspond to a category (clear, almost clear, mild, moderate, and severe, respectively) based on morphological descriptors.
Time frame: Baseline (pre-dose on Day 1) and Week 4
Percent Change From Baseline in Body Surface Area (BSA) Efficacy at Week 4
The percent BSA with atopic dermatitis in a body region was determined by the number of handprints of atopic dermatitis skin in that region: head and neck, upper limbs, trunk including axillae, lower limbs including buttocks. In the handprint method, the full palmar hand of the participant (i.e., the participant's fully extended palm, fingers and thumb together) represented approximately 1% of the total BSA. What is reported is the percent change from baseline in BSA affected.
Time frame: Baseline (pre-dose on Day 1) and Week 4
Change From Baseline in the EASI Clinical Signs Severity Sum Score at Week 4
The EASI Clinical Signs Severity Sum Score was derived from the EASI. The Clinical Signs Severity Scores on the 4-point scale for dermatitis lesions were summed in each EASI body region. The sum of the Clinical Signs Severity Score in each EASI body region was then totaled across the 4 EASI body regions to provide an EASI Clinical Signs Severity Sum Score, which ranged from 0 to 48, with higher scores representing greater severity of atopic dermatitis.
Time frame: Baseline (pre-dose on Day 1) and Week 4
Eligibility included male or female participants, 18 to 60 years of age (inclusive), who had a clinical diagnosis of atopic dermatitis for at least 6 months and clinically stable for \>=1 month.
| Milestone | Tofacitinib 20 mg/g BID | Vehicle BID |
|---|---|---|
| Started | 35 | 34 |
| Completed | 34 | 31 |
| Not completed | 1 | 3 |
| Withdrew: Adverse event | 0 | 2 |
| Withdrew: Lost to follow-up | 1 | 0 |
| Withdrew: Withdrawal by subject | 0 | 1 |
The EASI quantifies the severity of a participant's atopic dermatitis based on both lesion severity and the percent of BSA affected. The EASI is a composite scoring by the atopic dermatitis clinical evaluator of the degree of erythema, induration/papulation, excoriation, and lichenification (each scored separately) for each of 4 body regions, with adjustment for the percent of BSA involved for each body region and for the proportion of the body region to the whole body. The EASI score can vary in increments of 0.1 and range from 0.0 to 72.0, with higher scores representing greater severity of atopic dermatitis. What is reported is the percent change from baseline in EASI scores.
| percent change | Tofacitinib 20 mg/g BID | Vehicle BID |
|---|---|---|
| Percent Change From Baseline in Eczema Area and Severity Index (EASI) Total Score at Week 4 | -81.7 ± 6.31 | -29.9 ± 6.46 |
The PGA score assesses the overall severity of atopic dermatitis. Scores range from 0 to 4 and correspond to a category (clear, almost clear, mild, moderate, and severe, respectively) based on morphological descriptors.
| percentage of participants | Tofacitinib 20 mg/g BID | Vehicle BID |
|---|---|---|
| Proportion of Participants Achieving Physician's Global Assessment (PGA) Response of Clear or Almost Clear at Week 4 | 71.4 | 20.6 |
The PGA score assesses the overall severity of atopic dermatitis. Scores range from 0 to 4 and correspond to a category (clear, almost clear, mild, moderate, and severe, respectively) based on morphological descriptors.
| percentage of participants | Tofacitinib 20 mg/g BID | Vehicle BID |
|---|---|---|
| Proportion of Participants With Response of Clear or Almost Clear and Greater Than or Equal to (>=) 2 Grade/Point Improvement From Baseline at Week 4 | 65.7 | 11.8 |
The percent BSA with atopic dermatitis in a body region was determined by the number of handprints of atopic dermatitis skin in that region: head and neck, upper limbs, trunk including axillae, lower limbs including buttocks. In the handprint method, the full palmar hand of the participant (i.e., the participant's fully extended palm, fingers and thumb together) represented approximately 1% of the total BSA. What is reported is the percent change from baseline in BSA affected.
| percent change | Tofacitinib 20 mg/g BID | Vehicle BID |
|---|---|---|
| Percent Change From Baseline in Body Surface Area (BSA) Efficacy at Week 4 | -72.7 ± 34.1 | -30.2 ± 39.4 |
The EASI Clinical Signs Severity Sum Score was derived from the EASI. The Clinical Signs Severity Scores on the 4-point scale for dermatitis lesions were summed in each EASI body region. The sum of the Clinical Signs Severity Score in each EASI body region was then totaled across the 4 EASI body regions to provide an EASI Clinical Signs Severity Sum Score, which ranged from 0 to 48, with higher scores representing greater severity of atopic dermatitis.
| units on a scale | Tofacitinib 20 mg/g BID | Vehicle BID |
|---|---|---|
| Change From Baseline in the EASI Clinical Signs Severity Sum Score at Week 4 | -11.4 ± 5.3 | -4.1 ± 4.5 |
Collected over Baseline up to 28 days after last study drug administration. Non-serious events are listed at a 0% frequency threshold.
| Group | Deaths | Serious | Other |
|---|---|---|---|
| Tofacitinib 20 mg/g BID | — | 0/35 (0%) | 11/35 (31.4%) |
| Vehicle BID | — | 0/34 (0%) | 19/34 (55.9%) |
| Event | Tofacitinib 20 mg/g BID | Vehicle BID |
|---|---|---|
| Blood creatine phosphokinase increasedInvestigations | 0/35 | 3/34 |
| Dermatitis contactSkin and subcutaneous tissue disorders | 0/35 | 3/34 |
| NasopharyngitisInfections and infestations | 2/35 | 2/34 |
| HeadacheNervous system disorders | 1/35 | 2/34 |
| Conjunctivitis allergicEye disorders | 0/35 | 1/34 |
| Application site pruritusGeneral disorders | 1/35 | 1/34 |
| Seasonal allergyImmune system disorders | 0/35 | 1/34 |
| Upper respiratory tract infectionInfections and infestations | 0/35 | 1/34 |
| Arthropod biteInjury, poisoning and procedural complications | 0/35 | 1/34 |
| SunburnInjury, poisoning and procedural complications | 0/35 | 1/34 |
The full analysis set included all participants who were randomized and received at least 1 dose of study drug.
| Age, Continuous(years) | Tofacitinib 20 mg/g BID | Vehicle BID | Total |
|---|---|---|---|
| Mean | 32.4 ± 9.8 | 30.4 ± 10.4 | 31.4 ± 10.1 |
| Sex: Female, Male(Participants) | Tofacitinib 20 mg/g BID | Vehicle BID | Total |
|---|---|---|---|
| Female | 19 | 18 | 37 |
| Male | 16 | 16 | 32 |
The record gives a start of Dec 2013, a primary completion of Sep 2014 and a completion of Sep 2014. It does not say whether these dates are actual or estimated.
Results were first posted in Oct 2015, 1 year 1 month after primary completion.
How these figures are worked out, and which studies are left out of them.
This study is completed, as verified in Sep 2015. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Studies of the drug tested here: Tofacitinib